182 related articles for article (PubMed ID: 12654050)
1. Predictive value of pretransplantation cyclosporine pharmacokinetic studies on initial post-transplantation dosing in pediatric kidney allograft recipients.
Seikku P; Hoppu K; Jalanko H; Holmberg C
Pediatr Transplant; 2003 Apr; 7(2):102-10. PubMed ID: 12654050
[TBL] [Abstract][Full Text] [Related]
2. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
3. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
International Neoral Renal Transplantation Study Group.
Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
[TBL] [Abstract][Full Text] [Related]
7. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
8. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A monitoring--how to account for twice and three times daily dosing.
Fanta S; Backman JT; Seikku P; Holmberg C; Hoppu K
Pediatr Nephrol; 2005 May; 20(5):591-6. PubMed ID: 15772834
[TBL] [Abstract][Full Text] [Related]
10. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.
Kaplan B; Meier-Kriesche HU; Napoli KL; Kahan BD
Ther Drug Monit; 1999 Feb; 21(1):44-9. PubMed ID: 10051053
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
[TBL] [Abstract][Full Text] [Related]
12. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients.
Dunn S; Cooney G; Sommerauer J; Lindsay C; McDiarmid S; Wong RL; Chang CT; Smith HT; Choc MG
Transplantation; 1997 Jun; 63(12):1762-7. PubMed ID: 9210501
[TBL] [Abstract][Full Text] [Related]
15. Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra.
Terrill CJ; Lill J; Somerville KT; Sherbotie JR
J Ren Nutr; 2003 Jan; 13(1):26-30. PubMed ID: 12563620
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients.
Frauca E; Diaz MC; de la Vega A; Hierro L; Camarena C; Muñoz Bartolo G; Díez R; Murcia J; Gámez M; Sanchez Peinado C; López Santamaría M; Andrés I; Jara P
Pediatr Transplant; 2007 Aug; 11(5):530-5. PubMed ID: 17631022
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
19. Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients.
Sagedal S; Asberg A; Hartmann A; Bergan S; Berg KJ
Clin Transplant; 1998 Dec; 12(6):553-6. PubMed ID: 9850449
[TBL] [Abstract][Full Text] [Related]
20. Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation.
Browne BJ; Holt CO; Emovon OE
Clin Transplant; 2001; 15 Suppl 6():51-4. PubMed ID: 11903387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
